National Vaccine Adverse Event Reporting Survey and Etiology

COVID-19 Clinical Trial

— NVAERS  

Official title:

National Vaccine Adverse Event Reporting Survey to Determine the Etiology of Vaccine-Induced Injury

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05095844
• Other study ID #: NVAERS_1121
• Status: Recruiting
• Start date: March 15, 2022
• Est. completion date: April 1, 2024

Study information

• Verified date: March 2022
• Source: Neuroganics LLC
• Contact: Donald C Cooper, Ph.D.
• Phone: 303.733.6353
• Email: vaccinestudy[@]protonmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.

The primary goal of this study is to create a national database and gather vaccine-associated serious adverse events/injury data from newly vaccinated individuals in the US in order to identify the possible underlying causal relationships and plausible underlying biological mechanisms. The project aims to identify the genetic determinants of vaccine-induced adverse response by studying host genetics. We plan to use whole genome sequencing to identify single nucleotide polymorphisms associated with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological symptoms induced by vaccine administration.

The secondary goal is to establish criteria that enable classification of vaccine-induced adverse events/injuries compare data from our database with the official Vaccine Injury Table National Vaccine Injury Compensation Program on or after March 21, 2017.

The tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.

Description:

Vaccinations are typically administered to healthy persons and often are mandated by states or federal authorities as a condition for school attendance or military service in order to prevent the spread of infectious diseases. Because vaccines are either mandated or recommended for vulnerable groups, such as children or the elderly, vaccines are often held to a higher standard of safety by the FDA than other medical products.

Due to the vast numbers of vaccine doses administered in the US there is a need to gather quality information on serious vaccine-associated adverse events leading to serious injury. Vaccine-induced adverse events are typically reported in the CDC Vaccine Adverse Event Reporting System (VAERS) database, which contains information on unverified reports of adverse events (illnesses, health problems and/or symptoms) following immunization with US-licensed vaccines. Reports are accepted from anyone and can be submitted electronically at www.vaers.hhs.gov.

The primary goal for this observational study is to establish an independent national database to classify vaccine-associated serious adverse events/injury data from vaccinated individuals. The plan is to gather survey data and health information from newly vaccinated individuals who have experienced serious adverse effects in order to help understand the possible causal relationships and plausible biological mechanisms underlying serious adverse events/injuries. The project aims to identify the genetic determinants of vaccine-induced adverse response by studying host genetics. We plan to use Nebula Genomics platform for whole genome sequencing to identify single nucleotide polymorphisms associated with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological symptoms induced by vaccine administration.

The secondary goal is to gather medical history and survey data from recently vaccinated individuals in order to develop a vaccine-injury risk assessment tool which may be used to predict individual vulnerability to vaccine adverse events/injury.

The tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100000
• Est. completion date: April 1, 2024
• Est. primary completion date: April 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 99 Years

Eligibility

Inclusion Criteria:

Individuals who have received at least one vaccine dose of ANY of the following vaccines (below) and experienced adverse reaction within 60 days of vaccine administration:

1. Pfizer-BioNTech COVID-19 Vaccine

2. Moderna COVID-19 Vaccine

3. J&J/Janssen COVID-19 Vaccine

4. Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT)

5. Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib)

6. Hepatitis A (e.g., HAV)

7. Hepatitis B (e.g., HBV)

8. Human papillomavirus (e.g., HPV)

9. Seasonal influenza (e.g., Flu)

10. Measles (e.g., MMR)

11. Mumps (e.g., MMR, MR, M)

12. Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C)

13. Pertussis (e.g., DTP, DTaP, Tdap)

14. Pneumococcal conjugate (e.g., PCV)

15. Polio (e.g., OPV or IPV)

16. Rotavirus (e.g., RV)

17. Rubella (e.g., MMR, MR, R)

18. Tetanus (e.g., Td)

19. Varicella (e.g., VAR).

Exclusion Criteria:

1. Non citizens or permanent residents of the US

2. Individuals who have not received at least one vaccine dose in the past 3 years.

3. Individuals whose vaccine was administered more than 60 days before symptoms of the serious adverse event.

-

Related Conditions & MeSH terms

• Blood Clot
• Corona Virus Infection
• Coronavirus Infections
• COVID-19
• Guillain-Barré
• Guillain-Barre Syndrome
• Influenza
• Neuritis
• Thrombocytopenia
• Thrombosis
• Vaccine Adverse Reaction
• Vaccine Reaction
• Vasculitis

Intervention

Biological:
• vaccinated
Pfizer-BioNTech COVID-19 Vaccine, Moderna or J&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)

Locations

Country	Name	City	State
United States	Neuroganics LLC	Northglenn	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
Neuroganics LLC	Ramos Injury Law Firm

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Event	Reported adverse event occurring less than 60 days after administration of vaccine.	2 years
Secondary	Vaccine manufacturer efficacy	Comparison of multiple vaccine manufacturers for adverse events.	2 years